The Regulatory Academy Blog
Office Hours
The questions every cohort asks — about the career, the craft, and the first job — answered properly, in writing, by someone who does the work.
The Blog
Asked in Office Hours.
Answered in Writing.
Short, practical essays on careers and craft in regulatory affairs — the questions every cohort asks, answered properly once.
83 essays
-
Sep 22026
How to Review a Colleague’s Regulatory Draft
A colleague’s draft deserves more than “looks good.” What a useful reviewer actually checks, and how to write comments the author can act on.
-
Sep 12026
How to Brief a Team on a New FDA Requirement
A new FDA requirement means nothing to your team until you translate it into what changes for their program, by when, and who has to act on it.
-
Sep 12026
How to Run a Submission Readiness Review
A readiness review is the last honest look before you submit, not a repeat of the RTA checklist. What it actually checks, and who belongs in the room.
-
Sep 12026
How to Push Back on a Launch Timeline You Didn’t Set
Regulatory doesn’t set FDA’s review clock, but pretending the whole timeline is out of your hands wastes your credibility. What to say instead.
-
Aug 312026
How to Read a Federal Register Notice
A Federal Register notice is not the regulation itself, and reading it like one wastes time. Where to look first, and what a docket number unlocks.
-
Aug 302026
What Breakthrough Device Designation Actually Changes
Breakthrough Devices Program designation buys FDA’s attention and priority review, not a lower bar for clearance. What actually changes, and what doesn’t.
-
Aug 292026
Being the Only Regulatory Voice in the Room
Being the only regulatory voice in a fast-moving room means separating what’s required from what’s your call. How to hold that line without losing the room.
-
Aug 292026
Writing an Indications for Use Statement You Can Defend
An indications for use statement quietly sets the boundary of your 510(k). How to write one your testing actually supports, and defend it after clearance.
-
Aug 292026
How to Read an FDA Advisory Committee Transcript
An advisory committee’s vote is FDA’s input, not its decision. How to read the transcript for the concerns and phrasing most likely to shape what happens next.
-
Aug 282026
Handling a Regulatory Decision You Disagree With
Disagreeing with a regulatory determination is normal; how you raise it shapes your credibility. A practical way to make your case, then know when to let it go.
-
Aug 282026
Your First Regulatory Affairs Performance Review
Your first performance review rewards work that’s easy to miss from outside the function. How to document what you decided, before the conversation happens.
-
Aug 282026
Responding to an FDA Additional Information Request
An FDA Additional Information request pauses your submission, not your case. How to answer exactly what’s asked without reopening what’s already settled.
-
Aug 272026
How to Run a Study Group for the RAC Exam
Studying alone for the RAC exam works until it doesn’t. How to structure a small peer study group so it forces retrieval and exposes blind spots.
-
Aug 262026
Building a Working File of Predicate and Precedent Devices
Bookmarking 510(k) summaries isn’t the same as building expertise. How to keep a working file of predicate devices that gets more useful every time you use it.
-
Aug 262026
Teaching a Colleague What Regulatory Affairs Actually Does
A short, honest session on what regulatory affairs actually owns changes how engineers and other colleagues work with you — far more than a lecture on the CFR.
-
Aug 262026
Giving a Regulatory Update Executives Will Actually Use
A status update that lists activity instead of decisions won’t get read twice. What a submission update should say, and what can wait for the next one.
-
Aug 252026
The First Regulatory Affairs Hire
What changes when you’re the only regulatory affairs person at a company, with no existing function, no playbook, and no one to calibrate against.
-
Aug 252026
How to Read an MDSAP Audit Report
A single MDSAP audit can satisfy five regulators at once. How the report is structured, how findings are graded, and what a clean one doesn’t tell you.
-
Aug 252026
How to Write a Response to an FDA Warning Letter
A warning letter response isn’t a corrective action plan with a cover page. What FDA is actually evaluating, and why the signature on it matters.
-
Aug 242026
How to Read an FDA Postmarket Surveillance Order
A postmarket surveillance order isn’t a penalty. It’s FDA requiring a study after clearance, tied to Section 522 — and what the order asks a manufacturer to do.
-
Aug 242026
How to Read an FDA Safety Communication
An FDA safety communication carries no legal force of its own. What one actually is, why FDA issues them, and how a practitioner should read one correctly.
-
Aug 242026
How to Work With a Regulatory Affairs Consultant
Hiring a regulatory consultant doesn’t move the responsibility off your desk. How to scope the engagement, and what a consultant can’t take off your plate.
-
Aug 232026
How to Read an FDA Establishment Inspection Report
A Form 483 lists what an investigator observed. The Establishment Inspection Report is FDA’s own narrative behind it, and getting one takes a records request.
-
Aug 232026
How to Read an FDA Not Substantially Equivalent Letter
An NSE letter doesn’t end a 510(k) pathway — it forecloses one predicate comparison. What the letter says, and the three ways forward after it.
-
Aug 232026
Startups vs. Established Companies in Regulatory Affairs
Neither path is inherently better for a regulatory affairs career — what changes is the pace, the mentorship, and how early you're trusted with real scope.
-
Aug 222026
Building expertise in one product area
Depth in one product area compounds faster than breadth ever does early on — what that actually means when you rarely get to choose the assignment.
-
Aug 222026
How to read an FDA 513(g) response
A 513(g) response tells you how FDA would classify a device — it is not a clearance, and reading it as one is the most common way this document gets misused.
-
Aug 222026
How to read an FDA import alert
An import alert puts a firm’s shipments on detention before they reach a review — what triggers one, how DWPE works, and how a listing actually gets removed.
-
Aug 212026
How to read an FDA advisory committee briefing
Before a panel votes, FDA and the sponsor each publish a briefing document — what the two documents contain, and where they tend to disagree.
-
Aug 212026
How to read an FDA notice of inspection
Form FDA 482 is what an investigator presents at your door under Section 704 of the FD&C Act — what it establishes, and what to do in the first hour.
-
Aug 212026
How to negotiate a regulatory affairs job offer
Compensation is usually fixed by the time an offer lands. Start date, level, relocation, and exam support often are not — what to ask for, and how to ask.
-
Aug 202026
The case for keeping a regulatory decision log
A running record of the small judgment calls you make is worth more than memory once an audit or a new hire needs to understand how you got there.
-
Aug 202026
How to get value from a regulatory affairs conference
The sessions matter less than the conversations. What a trade conference rewards is different from what an FDA public meeting or a paid course rewards.
-
Aug 192026
How to read an FDA inspection classification
A Form FDA 483 lists observations. The classification that follows — NAI, VAI, or OAI — is what actually determines whether the story ends there.
-
Aug 192026
How to write an FDA 483 response
A 483 response isn’t a form to fill out. It’s a technical document that shapes whether FDA classifies the inspection as VAI or moves toward a Warning Letter.
-
Aug 192026
How regulatory affairs works with R&D
Regulatory affairs earns influence with engineering by showing up during design, not just at the end. Design controls give both functions a shared language.
-
Aug 182026
How FDA decides which center reviews your product
Combination products don’t pick their own review center. A Request for Designation is how a sponsor gets a binding answer instead of a guess.
-
Aug 182026
Moving from individual contributor to RA manager
The judgment that made you a strong specialist doesn’t automatically transfer once you’re responsible for someone else’s. What actually changes.
-
Aug 182026
How to read an FDA Untitled Letter
An Untitled Letter cites a real violation, without the deadline and escalation language a warning letter carries. Reading the difference correctly matters.
-
Aug 172026
How to read a predetermined change control plan
FDA can pre-authorize a defined set of future device changes inside the original submission. What a change control plan promises, and where its authority stops.
-
Aug 172026
What changes when you consult in regulatory affairs
The regulatory reasoning barely changes moving from in-house to consulting. What shifts is who owns the client relationship, the deadline, and the outcome.
-
Aug 172026
How to read a device’s UDI record in GUDID
Every device carries a Unique Device Identifier, and FDA publishes what it means in a public database. What its two halves tell you, and what they don’t.
-
Aug 162026
How to read an FDA complete response letter
When FDA finishes reviewing a drug application and the answer isn’t yes, it sends a Complete Response Letter instead of an approval letter. What that letter is built to do, and why you’ll rarely read the document itself.
-
Aug 162026
How to read an FDA De Novo classification order
When a novel, low-to-moderate-risk device has no predicate to compare against, FDA can grant it market authorization directly. What the resulting order actually says, and what it means for the next sponsor who reads it.
-
Aug 162026
From the bench to regulatory affairs
A research background gives you real, useful skills for this work — just not always the ones people assume, and not without some translation. What actually transfers, and what you have to learn from scratch.
-
Aug 152026
How to get value from an FDA public meeting
Advisory committee meetings and public workshops are open to attend, and sometimes to speak at. What they’re actually for, and the difference between a public meeting and a conversation about your own submission.
-
Aug 152026
How to read FDA’s IDE regulations
Before a device reaches the market, someone has to decide it is safe enough to study on people first. What an Investigational Device Exemption actually requires, and who makes that call.
-
Aug 142026
How to read FDA’s RTA checklist
Before anyone reviews the substance of your 510(k), someone checks whether it’s complete enough to review at all. What that first pass actually looks for.
-
Aug 142026
How to read FDA’s eSTAR submission template
eSTAR isn’t just a form to fill out — its structure previews how a reviewer will work through your file, long before they open it.
-
Aug 142026
Building a work sample with no RA experience
You can’t point to a track record you don’t have yet. How to build something concrete that shows the judgment a hiring manager is actually screening for.
-
Aug 132026
The regulatory affairs career ladder, explained
Associate, specialist, manager — titles change, but what earns the next one is judgment, not tenure. What shifts at each rung, and how to tell you’re ready.
-
Aug 132026
How to prepare for an FDA pre-submission meeting
A Pre-Sub is one chance to get FDA’s read before you build the file. What to bring, what to ask, and how the feedback actually gets used.
-
Aug 132026
How to read an FDA product classification entry
Every cleared device carries a product code that unlocks its regulatory history. How to read a classification entry, and what each field tells you.
-
Aug 82026
How to choose a regulatory affairs certificate program
A certificate program’s landing page sells an outcome. Only the syllabus shows what you’ll actually learn — and whether it’s built for the job you want.
-
Aug 72026
How to read a medical device report
MAUDE is public and searchable, and a report in it is an allegation, not a finding. Read the coded fields as an index, not a diagnosis.
-
Aug 72026
How to read an FDA recall
A recall notice looks alarming and is almost always mundane. What the Class I, II, and III label is actually measuring — and what it isn’t.
-
Aug 72026
Continuing education in regulatory affairs
A credential earned once goes stale the moment the rule underneath it changes. The free channels, the tracking habit, and why training has to leave a record.
-
Aug 62026
How to write a regulatory rationale you can defend
A rationale isn’t finished when it reads well. It’s finished when it survives someone trying to take it apart.
-
Aug 62026
Moving from quality into regulatory affairs
A quality background covers more regulatory ground than the job title suggests — but the move asks for a skill quality work doesn’t train.
-
Aug 62026
How to read a regulatory affairs job posting
Regulatory affairs job postings use inconsistent titles and requirement lists. Here’s how to read one closely before you apply.
-
Aug 52026
How to build a regulatory intelligence habit
Tracking regulatory change is a habit built over a career, not a project you finish once and move on from.
-
Aug 52026
How to read a 510(k) summary
FDA publishes a public summary for every 510(k) clearance. Here’s what it can tell you, and what it leaves out.
-
Aug 52026
Your first 90 days in regulatory affairs
The first ninety days in a new regulatory affairs role are for orientation, not output.
-
Aug 42026
Getting value from a regulatory affairs course
Enrolling in a course is easy. Getting real value from it takes more deliberate effort than just showing up and taking notes.
-
Aug 32026
How to get a useful review of your draft
A draft no one but its author has read is not ready to submit. How to ask for a review that finds a real problem, instead of one that just signs off on it.
-
Aug 32026
How to study for the RAC exam
Deciding to sit for the RAC is one question. Studying for it is another — a routine built around scenarios and primary sources, not flashcards.
-
Aug 32026
How a regulation actually changes
A regulation does not change the moment an agency decides it should. The rulemaking process, and why the effective date is rarely the whole story.
-
Aug 22026
How to read a Form FDA 483
The observations on a 483 are an investigator’s judgment, not a verdict — and the response you write in the days after usually matters more than what is written on the form.
-
Aug 22026
How to read a recognized consensus standard
Citing a consensus standard from memory is not the same as checking what FDA’s recognition entry for it actually covers today. How to read one closely enough to know the difference.
-
Aug 22026
Building a professional network in regulatory affairs
A network built only during a job search reads exactly like what it is. How to build professional relationships in regulatory affairs starting with the people already in the room.
-
Aug 12026
How to explain a regulatory decision
The reasoning behind a regulatory call is usually sound. The explanation of it, to the colleague who was not in the room when it was made, often is not — and an unexplained decision gets re-argued indefinitely, whether or not it was right.
-
Aug 12026
How to read a regulation, not just the guidance
Guidance documents are the readable version, so most people learn FDA’s rules from them first. But guidance is a paraphrase of the agency’s current thinking — the regulation is the enforceable text, and reading it directly is a different, learnable skill.
-
Aug 12026
Finding a mentor in regulatory affairs
There is no residency or licensing exam that hands you regulatory judgment. Almost everyone good at this work learned the parts that matter most from someone who happened to be generous with their reasoning.
-
Jul 312026
Working with an FDA reviewer during a submission
The review clock does not stop for good manners, but a submission that moves is usually the one whose answers were anticipated rather than argued with. What actually happens once a submission is in review, and how practitioners work with FDA rather than around it.
-
Jul 312026
Writing a regulatory affairs resume from adjacent work
Almost nobody arrives at regulatory affairs holding a regulatory affairs degree. How to translate quality, clinical, technical-writing, or bench experience into a resume a regulatory hiring manager actually reads — without inventing experience you don’t have.
-
Jul 312026
A day in regulatory affairs — what the work looks like
No two days look alike, and anyone who tells you otherwise is describing a slow week. But the work reliably breaks into the same small set of categories — and it’s worth seeing that shape before you accept an offer, not after.
-
Jul 282026
Teaching yourself regulatory affairs — what actually works
No employer hands you a curriculum before you have the job. What self-directed study actually looks like when it works, and the two habits that quietly waste a year of it.
-
Jul 272026
Moving between devices and pharma in regulatory affairs
The FD&C Act covers both, and a device reviewer and a drug reviewer are trained to ask almost nothing alike. What carries over when you move between the two, and what you have to relearn from zero.
-
Jul 272026
How to read an FDA warning letter
The observations were never a secret — the company saw them first, at the inspection’s close. What changes at the warning-letter stage, and how practitioners read one for the pattern behind the citations.
-
Jul 272026
Is the RAC certification worth it?
RAPS’ own credential is the closest thing this profession has to a license — and it isn’t one. What the exam actually tests, what a year of study costs you, and who it’s really for.
-
Jul 232026
How to get into regulatory affairs — the honest map
No degree points straight at this profession, and almost every posting asks for experience you don’t have yet. The routes that actually produce first jobs — and the ones that quietly don’t.
-
Jul 232026
How to read an FDA guidance document
Guidance is not law — but reviewers read it as a map of their own expectations. How practitioners take a forty-page PDF apart in an hour, and what they write down.
-
Jul 232026
Your first regulatory interview — what they listen for
The questions are predictable; the listening is not. What interviewers are actually testing when they ask about a submission you have never run — and how to answer without bluffing.
Nothing matches that search.
One email a month. Worth opening.
New essays and new courses, in one short email each month. No sales sequence. Unsubscribe anytime.
Essays Start the Thought. Courses Finish It.
Office Hours answers the questions around the work. The courses teach the work itself — free, practitioner-written, and structured so each lesson builds on the last. Start with the 510(k).